miR147 plays a crucial role in promoting mucosal integrity and regulating intestinal inflammation. As a protective microRNA, miR147 is specifically enriched in intestinal epithelial cells (IECs), particularly in differentiated enterocytes at the luminal surface of the colon.
miR147 plays a crucial role in promoting mucosal integrity and regulating intestinal inflammation. As a protective microRNA, miR147 is specifically enriched in intestinal epithelial cells (IECs), particularly in differentiated enterocytes at the luminal surface of the colon. Its expression is intrinsic to epithelial differentiation and not dependent on microbial exposure, as demonstrated in germ-free mice. During inflammation, miR147 expression is upregulated in response to cytokine-driven signals, as observed in dextran sodium sulfate (DSS)-induced colitis models and inflammatory conditioned media experiments.
Functionally, miR147 is vital for maintaining epithelial barrier integrity and promoting mucosal healing during inflammation. Global and epithelial-specific miR147 knockout mice exhibit severe colitis characterized by significant body weight loss, shortened colons, epithelial destruction, and increased intestinal permeability. Transcriptomic analysis revealed that miR147 suppresses proinflammatory and mitochondrial metabolism genes, particularly Ndufa4, a mitochondrial complex IV-associated gene. Ndufa4 was identified as a direct target of miR147, and its dysregulation in miR147-deficient tissues leads to disrupted metabolism and weakened barrier function. Mechanistic studies confirmed that the miR147–Ndufa4 axis is essential for epithelial homeostasis, as mice engineered to lack the miR147 binding site in Ndufa4 mirrored the severe inflammation seen in miR147 knockouts.
Furthermore, miR147 supports robust type I interferon signaling in colonocytes, enhancing antiviral and anti-inflammatory defense while sustaining metabolic balance. The study suggests that miR147 mimics or Ndufa4-targeted therapies could restore mucosal healing and reduce inflammation, highlighting miR147 as a potential therapeutic target for inflammatory bowel disease (IBD) and colorectal cancer.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.